BioSpace News Archive

AMRA researchers together with Linköping University used personalized imaging-derived obesity phenotypes, based on a large, population-based study, to investigate cardiometabolic risk stratification in individuals with obesity.

Aurora Spine Corporation today announced that the first patient has been enrolled for its multicenter study of DEXA-C TM Cervical Interbody System.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that long-term clinical study results from the U.S. ANAVEX®2-73-RS-001 (NCT03758924) study demonstrate disease modifying effect of ANAVEX®2-73 (blarcamesine) for adult patients with Rett syndrome.

Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce a corporate update and preliminary financial results of Q2-2023.

InflaRx N.V. today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal, Clinical Immunology, demonstrating the role of inflammasome NLRP3 activation in lupus nephritis.

Blue Water Biotech, Inc today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens.

Olink Holding AB announced the availability of new findings into the variability of the human proteome, based on measurements of approximately 1,500 proteins in over 50,000 participants from the UK Biobank.

Ovid Therapeutics Inc. today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs.